From injection therapies to natalizumab: views on the treatment of multiple sclerosis

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

(2011) Ludwig Kappos et al.   LANCET NEUROLOGY

Promising Emerging Therapies for Multiple Sclerosis

(2011) Gavin Giovannoni   NEUROLOGIC CLINICS

Too much of a good thing?: IRIS with natalizumab-associated PML

(2011) J. R. Berger   NEUROLOGY

Immune reconstitution inflammatory syndrome in natalizumab-associated PML

(2011) I. L. Tan et al.   NEUROLOGY

Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome

(2011) D. T. Okuda et al.   NEUROLOGY

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

(2011) P. W. O'Connor et al.   NEUROLOGY

Switching Multiple Sclerosis Patients with Breakthrough Disease to Second-Line Therapy

(2011) Tamara Castillo-Trivino et al.   PLoS One

Natalizumab dosage suspension: Are we helping or hurting?

(2010) Timothy W. West et al.   ANNALS OF NEUROLOGY

Anti-JC virus antibodies: Implications for PML Risk Stratification

(2010) Leonid Gorelik et al.   ANNALS OF NEUROLOGY

Natalizumab and Progressive Multifocal Leukoencephalopathy

(2010) Clemens Warnke et al.   ARCHIVES OF NEUROLOGY

Efficacy and tolerability of natalizumab in relapsing–remitting multiple sclerosis patients: a post-marketing observational study

(2010) F. Sangalli et al.   NEUROLOGICAL SCIENCES

Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials

(2010) D. Bates   NEUROLOGY

MRI criteria for MS in patients with clinically isolated syndromes

(2010) X. Montalban et al.   NEUROLOGY

Pharmacological Treatment of Early Multiple Sclerosis

(2009) Olaf Stüve et al.   DRUGS

What can be learned from open direct comparative trials in multiple sclerosis?

(2009) Omar Khan   JOURNAL OF THE NEUROLOGICAL SCIENCES

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

(2009) Ludwig Kappos et al.   LANCET NEUROLOGY

250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

(2009) Paul O'Connor et al.   LANCET NEUROLOGY

Monoclonal antibodies in MS: Mechanisms of action

(2009) B. Bielekova et al.   NEUROLOGY

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

(2009) B. O. Khatri et al.   NEUROLOGY

Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis

(2008) L. K. Fisniku et al.   BRAIN

Switching algorithms: from one immunomodulatory agent to another

(2008) Patricia K. Coyle   JOURNAL OF NEUROLOGY

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

(2008) Daniel D Mikol et al.   LANCET NEUROLOGY

Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis

(2008) T Vollmer et al.   Multiple Sclerosis Journal

Early treatment of multiple sclerosis to prevent neurologic damage

(2008) P. K. Coyle   NEUROLOGY

Disease-modifying therapy in multiple sclerosis: Update and clinical implications

(2008) D. S. Goodin   NEUROLOGY

Incidental MRI anomalies suggestive of multiple sclerosis: The radiologically isolated syndrome

(2008) D. T. Okuda et al.   NEUROLOGY